Inovio Historical Income Statement
| INO Stock | USD 10.16 0.21 2.03% |
Historical analysis of Inovio Pharmaceuticals income statement accounts such as Total Revenue of 790.4 K or Other Operating Expenses of 73.9 M can show how well Inovio Pharmaceuticals performed in making a profits. Evaluating Inovio Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Inovio Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Inovio Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Inovio Pharmaceuticals is a good buy for the upcoming year.
Inovio |
About Inovio Income Statement Analysis
Inovio Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Inovio Pharmaceuticals shareholders. The income statement also shows Inovio investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Inovio Pharmaceuticals Income Statement Chart
Inovio Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Inovio's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Inovio Pharmaceuticals revenue and expense. Inovio Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Inovio Pharmaceuticals' Depreciation And Amortization is very stable compared to the past year. As of the 24th of April 2024, Total Other Income Expense Net is likely to grow to about 114.8 K, while Interest Expense is likely to drop about 1.2 M. Add Fundamental
Total Revenue
Total revenue comprises all receipts Inovio Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Inovio Pharmaceuticals. It is also known as Inovio Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Inovio Pharmaceuticals income statement and represents the costs associated with goods and services Inovio Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Inovio Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Inovio Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.At this time, Inovio Pharmaceuticals' Depreciation And Amortization is very stable compared to the past year. As of the 24th of April 2024, Total Other Income Expense Net is likely to grow to about 114.8 K, while Interest Expense is likely to drop about 1.2 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 1.8M | 10.3M | 832.0K | 790.4K | Interest Expense | 1.9M | 1.3M | 1.2M | 1.2M |
Inovio Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Inovio Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Inovio Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 5.5M | 47.9M | 7.9M | (979.2K) | 3.5M | 4.1M | |
| Interest Expense | 7.9M | 8.7M | 1.9M | 1.3M | 1.2M | 1.2M | |
| Total Revenue | 4.1M | 7.4M | 1.8M | 10.3M | 832.0K | 790.4K | |
| Gross Profit | (83.9M) | (86.8M) | (3.0M) | 4.8M | (2.7M) | (2.5M) | |
| Other Operating Expenses | 115.2M | 131.5M | 303.0M | 277.8M | 136.1M | 73.9M | |
| Operating Income | (111.1M) | (124.1M) | (301.2M) | (267.6M) | (135.2M) | (128.5M) | |
| Ebit | (111.1M) | (124.1M) | (301.2M) | (267.6M) | (135.2M) | (128.5M) | |
| Research Development | 88.0M | 94.2M | 249.2M | 187.7M | 88.5M | 52.1M | |
| Ebitda | (105.6M) | (76.2M) | (293.3M) | (268.6M) | (131.7M) | (125.1M) | |
| Cost Of Revenue | 88.0M | 94.2M | 4.7M | 5.5M | 3.5M | 3.3M | |
| Total Operating Expenses | 115.2M | 131.5M | 303.0M | 277.8M | 132.6M | 73.5M | |
| Income Before Tax | (120.8M) | (162.9M) | (303.2M) | (277.7M) | (135.1M) | (128.4M) | |
| Total Other Income Expense Net | (9.7M) | (38.8M) | (2.0M) | (10.1M) | 109.3K | 114.8K | |
| Net Income | (120.6M) | (215.1M) | (305.4M) | (287.7M) | (135.1M) | (128.4M) | |
| Income Tax Expense | (257.3K) | 52.2M | 2.2M | 10.0M | 2.0 | 1.9 | |
| Selling General Administrative | 27.2M | 37.2M | 53.8M | 90.2M | 47.6M | 50.0M | |
| Net Income From Continuing Ops | (120.5M) | (162.9M) | (303.2M) | (277.7M) | (164.6M) | (172.8M) | |
| Non Operating Income Net Other | 1.3M | (72.9M) | 3.3M | (1.2M) | (1.1M) | (1.2M) | |
| Net Income Applicable To Common Shares | (119.4M) | (166.4M) | (303.7M) | (279.8M) | (251.8M) | (239.2M) | |
| Interest Income | 2.6M | 3.3M | 3.4M | 4.8M | 8.2M | 8.6M | |
| Net Interest Income | (5.3M) | (5.4M) | 1.4M | 3.5M | 6.9M | 7.3M | |
| Reconciled Depreciation | 5.5M | 4.6M | 4.7M | 5.5M | 4.7M | 5.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Inovio Stock analysis
When running Inovio Pharmaceuticals' price analysis, check to measure Inovio Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inovio Pharmaceuticals is operating at the current time. Most of Inovio Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Inovio Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inovio Pharmaceuticals' price. Additionally, you may evaluate how the addition of Inovio Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Inovio Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.09) | Revenue Per Share 0.038 | Quarterly Revenue Growth (0.18) | Return On Assets (0.32) | Return On Equity (0.80) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.